Edwards Lifesciences (EW) Income from Continuing Operations (2009 - 2026)

Edwards Lifesciences' Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 380700000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 4.7% year-over-year to 380700000.0; the TTM figure through Mar 2026 stood at 1073100000.0 (down 25.2% YoY), while the FY2025 annual figure was 1056000000.0, down 24.36% from the prior year.
• Income from Continuing Operations was 380700000.0 for Q1 2026 at Edwards Lifesciences, up from 64200000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 406400000.0 in Q2 2022 to a low of 64200000.0 in Q4 2025.
• Historically, Income from Continuing Operations has averaged 318788235.29 across 5 years, with a median of 340500000.0 in 2023.
• The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations jumped 66.13% in 2023, then tumbled 81.39% in 2025.
• A 5-year view of Income from Continuing Operations shows it stood at 200500000.0 in 2022, then surged by 66.13% to 333100000.0 in 2023, then grew by 3.57% to 345000000.0 in 2024, then sank by 81.39% to 64200000.0 in 2025, then jumped by 492.99% to 380700000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 380700000.0 (Q1 2026), 64200000.0 (Q4 2025), and 292300000.0 (Q3 2025), per Business Quant data.